79 related articles for article (PubMed ID: 19564447)
1. Development and applications of a broad-coverage, TR-FRET-based kinase binding assay platform.
Lebakken CS; Riddle SM; Singh U; Frazee WJ; Eliason HC; Gao Y; Reichling LJ; Marks BD; Vogel KW
J Biomol Screen; 2009 Sep; 14(8):924-35. PubMed ID: 19564447
[TBL] [Abstract][Full Text] [Related]
2. Time Resolved-Fluorescence Resonance Energy Transfer platform for quantitative nucleosome binding and footprinting.
Wesley NA; Skrajna A; Simmons HC; Budziszewski GR; Azzam DN; Cesmat AP; McGinty RK
Protein Sci; 2022 Jun; 31(6):e4339. PubMed ID: 35634775
[TBL] [Abstract][Full Text] [Related]
3. KRAS4b:RAF-1 Homogenous Time-Resolved Fluorescence Resonance Energy Transfer Assay for Drug Discovery.
Larsen EK; Abreu-Blanco M; Rabara D; Stephen AG
Methods Mol Biol; 2024; 2797():159-175. PubMed ID: 38570459
[TBL] [Abstract][Full Text] [Related]
4. Development of Biochemical and Cellular Probes to Study RIPK1 Target Engagement.
Yu X; Lin H; Li F; Wang J; Lu D
ACS Med Chem Lett; 2024 Jun; 15(6):906-916. PubMed ID: 38894934
[TBL] [Abstract][Full Text] [Related]
5. Adjusting the Fitting of Fluorescence-Based Dose-Response Kinase Inhibition Assay to Account for Fluorescent Inhibitors.
Petit GA
Assay Drug Dev Technol; 2023 Oct; 21(7):331-336. PubMed ID: 37768806
[No Abstract] [Full Text] [Related]
6. Synthesis of a 3,7-Disubstituted Isothiazolo[4,3-
Grisez T; Ravi NP; Froeyen M; Schols D; Van Meervelt L; De Jonghe S; Dehaen W
Molecules; 2024 Feb; 29(5):. PubMed ID: 38474466
[TBL] [Abstract][Full Text] [Related]
7. Assessment of Functional Characterization and Comparability of Biotherapeutics: a Review.
Dash R; Singh SK; Chirmule N; Rathore AS
AAPS J; 2021 Dec; 24(1):15. PubMed ID: 34931298
[TBL] [Abstract][Full Text] [Related]
8. Mechanistic and Structural Features of PROTAC Ternary Complexes.
Casement R; Bond A; Craigon C; Ciulli A
Methods Mol Biol; 2021; 2365():79-113. PubMed ID: 34432240
[TBL] [Abstract][Full Text] [Related]
9. Optimization and validation of a DYRK1A TR-FRET assay for high-throughput screening.
Tarpley M; Caligan TB; Onyenwoke RU; Williams KP
MethodsX; 2021; 8():101383. PubMed ID: 34430279
[TBL] [Abstract][Full Text] [Related]
10. Identification of harmine and β-carboline analogs from a high-throughput screen of an approved drug collection; profiling as differential inhibitors of DYRK1A and monoamine oxidase A and for in vitro and in vivo anti-cancer studies.
Tarpley M; Oladapo HO; Strepay D; Caligan TB; Chdid L; Shehata H; Roques JR; Thomas R; Laudeman CP; Onyenwoke RU; Darr DB; Williams KP
Eur J Pharm Sci; 2021 Jul; 162():105821. PubMed ID: 33781856
[TBL] [Abstract][Full Text] [Related]
11. Controlling cellular distribution of drugs with permeability modifying moieties.
Richardson PL; Marin VL; Koeniger SL; Baranczak A; Wilsbacher JL; Kovar PJ; Bacon-Trusk PE; Cheng M; Hopkins TA; Haman ST; Vasudevan A
Medchemcomm; 2019 Jun; 10(6):974-984. PubMed ID: 31303996
[TBL] [Abstract][Full Text] [Related]
12. Flavones hydroxylated at 5, 7, 3' and 4' ameliorate skin fibrosis via inhibiting activin receptor-like kinase 5 kinase activity.
Zhang Y; Wang J; Zhou S; Xie Z; Wang C; Gao Y; Zhou J; Zhang X; Li Q
Cell Death Dis; 2019 Feb; 10(2):124. PubMed ID: 30741930
[TBL] [Abstract][Full Text] [Related]
13. Prodrugs for colon-restricted delivery: Design, synthesis, and in vivo evaluation of colony stimulating factor 1 receptor (CSF1R) inhibitors.
George DM; Huntley RJ; Cusack K; Duignan DB; Hoemann M; Loud J; Mario R; Melim T; Mullen K; Somal G; Wang L; Edmunds JJ
PLoS One; 2018; 13(9):e0203567. PubMed ID: 30192846
[TBL] [Abstract][Full Text] [Related]
14. Development of inverse electron demand Diels-Alder ligation and TR-FRET assays for the determination of ligand-protein target occupancy in live cells.
Marjanovic J; Baranczak A; Marin V; Stockmann H; Richardson PL; Vasudevan A
Medchemcomm; 2017 Apr; 8(4):789-795. PubMed ID: 30108797
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of polo-like kinase 4 (PLK4): a new therapeutic option for rhabdoid tumors and pediatric medulloblastoma.
Sredni ST; Bailey AW; Suri A; Hashizume R; He X; Louis N; Gokirmak T; Piper DR; Watterson DM; Tomita T
Oncotarget; 2017 Dec; 8(67):111190-111212. PubMed ID: 29340047
[TBL] [Abstract][Full Text] [Related]
16. Structure-guided development of covalent TAK1 inhibitors.
Tan L; Gurbani D; Weisberg EL; Hunter JC; Li L; Jones DS; Ficarro SB; Mowafy S; Tam CP; Rao S; Du G; Griffin JD; Sorger PK; Marto JA; Westover KD; Gray NS
Bioorg Med Chem; 2017 Feb; 25(3):838-846. PubMed ID: 28011204
[TBL] [Abstract][Full Text] [Related]
17. Positive Allosteric Modulation of the Glucagon-like Peptide-1 Receptor by Diverse Electrophiles.
Bueno AB; Showalter AD; Wainscott DB; Stutsman C; Marín A; Ficorilli J; Cabrera O; Willard FS; Sloop KW
J Biol Chem; 2016 May; 291(20):10700-15. PubMed ID: 26975372
[TBL] [Abstract][Full Text] [Related]
18. SAR Studies of 5-Aminopyrazole-4-carboxamide Analogues as Potent and Selective Inhibitors of
Huang W; Ojo KK; Zhang Z; Rivas K; Vidadala RS; Scheele S; DeRocher AE; Choi R; Hulverson MA; Barrett LK; Bruzual I; Siddaramaiah LK; Kerchner KM; Kurnick MD; Freiberg GM; Kempf D; Hol WG; Merritt EA; Neckermann G; de Hostos EL; Isoherranen N; Maly DJ; Parsons M; Doggett JS; Van Voorhis WC; Fan E
ACS Med Chem Lett; 2015 Dec; 6(12):1184-1189. PubMed ID: 26693272
[TBL] [Abstract][Full Text] [Related]
19. Target engagement and drug residence time can be observed in living cells with BRET.
Robers MB; Dart ML; Woodroofe CC; Zimprich CA; Kirkland TA; Machleidt T; Kupcho KR; Levin S; Hartnett JR; Zimmerman K; Niles AL; Ohana RF; Daniels DL; Slater M; Wood MG; Cong M; Cheng YQ; Wood KV
Nat Commun; 2015 Dec; 6():10091. PubMed ID: 26631872
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
